Arlington Heights, ILNCT05413421Now EnrollingIRB Ready

Metastatic Prostate Cancer Clinical Trial in Arlington Heights, IL

Access cutting-edge metastatic prostate cancer treatment through this clinical trial at a research site in Arlington Heights. Study-provided care at no cost to qualified participants.

Sponsored by ORIC Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Arlington Heights location

Preparing your pre-screening questions…

Expert Care in Arlington Heights

Access metastatic prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic prostate cancer treatment provided free

Apply for This Arlington Heights Location

Check if you qualify for this metastatic prostate cancer clinical trial in Arlington Heights, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Arlington Heights

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Arlington Heights site if eligible
  4. 4Begin participation

About This Metastatic Prostate Cancer Study in Arlington Heights

The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.

Sponsor: ORIC Pharmaceuticals

Who Can Participate

Inclusion Criteria

Patients with metastatic prostate cancer
Must have undergone bilateral orchiectomy or be willing to continue GnRH analogue or antagonist to maintain castrate levels of testosterone
Prior therapies: Part I (single agent ORIC-944 dose escalation): Any number of prior therapies are allowed, but must have progressed after at least one line of next generation ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide) and must not have received more than 2 chemotherapy regimens in the mCRPC setting Part II (ARPI combination dose escalation): Must have received only 1 prior line of ARPI (abiraterone, apalutamide, darolutamide, or enzalutamide) in any setting; may have also received up to 1 prior line of chemotherapy in the mCSPC setting Part III (ARPI combination dose optimization): In addition to up to 1 prior line of chemotherapy in the mCSPC setting:
Cohorts A and B: received only one 1 prior line of abiraterone in any setting
Cohorts C and D: received only one 1 prior line of apalutamide, darolutamide, or enzalutamide in any setting:
Evidence of progressive disease by PCWG3 criteria for study entry
rising PSA, defined as a minimum of 2 rising values obtained a minimum of one week apart with the latest result being at least 2.0 ng/mL (or 1.0 ng/mL if PSA rise is the only indication of progression), or
confirmation of 2 new bone lesions on last systemic therapy, or
soft tissue progression per RECIST 1.1
Measurable and/or evaluable disease by RECIST 1.1
Agreement and ability to undergo on-study punch skin biopsies and core tumor biopsies
ECOG performance status of 0 or 1
Adequate organ function

Exclusion Criteria

History or presence of CNS metastases, unless previously treated and stable
History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months
Known, symptomatic human immunodeficiency virus (HIV) infection
Active symptomatic Hepatitis B or C infection; patients with well controlled disease are eligible
Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, short gut syndrome, etc) or other malabsorption syndromes that would reasonably impact drug absorption per investigator judgement
Any other condition or circumstance (eg, clinical, psychological, familial, sociological, inability to swallow oral study drug) that, in the opinion of the investigator, may interfere with protocol compliance or contraindicates participation in the study

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Arlington Heights?

Yes, this clinical trial (NCT05413421) has an active research site in Arlington Heights, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Prostate Cancer Treatment Options in Arlington Heights, IL

If you're searching for metastatic prostate cancer treatment options in Arlington Heights, IL, this clinical trial (NCT05413421) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Arlington Heights research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Arlington Heights, IL

See all prostate cancer clinical trials recruiting in Arlington Heights — not just this study.

Browse Prostate Cancer Trials in Arlington Heights →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Arlington Heights?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Arlington Heights, IL